Comparative quantification of sarcolemmal proteins on immunostained www.selleckchem.com/products/azd9291.html muscle sections will be of use to establish both the abundance and localization of the protein. Moreover, it can be

applied to assess the efficacy of experimental therapies where only partial restoration or upregulation of the protein may occur. The study of proteins expressed either at the muscle fibre plasmalemma or in the basal lamina extracellular matrix is the basis for the diagnosis of a number of muscular dystrophies. These include Duchenne muscular dystrophy (DMD), characterized by the absence of the sarcolemma-associated cytoskeletal protein dystrophin, merosin-deficient congenital muscular dystrophy (MDC1A), due to the deficiency of the extracellular Ku 0059436 matrix protein laminin α2, and Ullrich congenital muscular dystrophy (UCMD), due to reduced collagen VI [1]. However,

in some of these conditions the protein deficiency is subtle and can be difficult to evaluate. Moreover, in some muscular dystrophies the patterns of secondary protein changes can aid in the diagnostic process [1]. Examples of these are cases of utrophin (UTR) upregulation in dystrophinopathies [2], dystrophin reduction in some sarcoglycanopathies [3,4], absent nitric oxide synthase in DMD and some Becker muscular dystrophy (BMD) patients [5,6], reduced laminin α2 in alpha dystroglycanopathies [7,8] or increases in laminin α5 in MDC1A and

dystroglycanopathies [9]. The quantitative study of the expression of these proteins and their localization is also vital for the correct assessment of experimental strategies designed to restore the missing protein in adequate amount, Avelestat (AZD9668) in the correct localization and interacting appropriately with other proteins in order to restore muscle function. Immunohistochemical techniques are frequently used to study the abundance and localization of proteins associated with these diseases [10]. Western blot analysis is also of use in the diagnosis of patients affected by muscular dystrophies, offering valuable semiquantitative data [11]. However, this technique requires greater amounts of sample and volume of antibodies and it only offers true quantitative information when studying samples far from the low and high detection limits [11,12]. Furthermore, in diseases like UCMD, where a reduction in collagen VI in the basal lamina rather than the interstitial connective tissue is a feature, reliable quantitative information of basal lamina protein levels is crucial [13]. In order to combine information on protein localization and abundance, we sought to develop a reproducible method to be able to quantitatively measure protein abundance in immunohistochemical labelled skeletal muscle.